COMMUNIQUÉS West-GlobeNewswire

Election of employee representatives to the Board of Directors of Novo Nordisk A/S
02/03/2026
Bagsværd, Denmark, 2 March 2026 – The employees in Novo Nordisk A/S have completed the election of employee representatives to the Board of Directors of Novo Nordisk A/S. The following employee representatives were [...]
CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting
02/03/2026
MINNEAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with [...]
Collegium to Participate in Upcoming Investor Conferences
02/03/2026
STOUGHTON, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Leerink Partners Global [...]
Palisade Bio Announces Participation in Two Upcoming Investor Conferences
02/03/2026
Carlsbad, CA, March 02, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor [...]
Health-ISAC Releases Its 2025 Annual Report
02/03/2026
Cultivating 15 Years of Global Health Sector Resilience ORLANDO, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Health Information Sharing and Analysis Center ( Health-ISAC ), the non-profit industry-led organization that [...]
Evaxion to announce business update and full year 2025 financial results on March 5, 2026
02/03/2026
COPENHAGEN, Denmark, March 2, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and [...]
BioSyent Announces Closing of the Acquisition of Oral Science Inc.
02/03/2026
MISSISSAUGA, Ontario, March 02, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture (TSXV): RX) is pleased to announce that it has successfully closed the previously-announced acquisition of Oral Science Inc [...]
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
02/03/2026
Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales in 2025 were $15.8 [...]
Emory Researchers Demonstrate the Power of Dynamic Digital Radiography to Quantify Functional Outcomes After Total Shoulder Arthroplasty
02/03/2026
WAYNE, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas, Inc. congratulates Emory Healthcare researchers, led by Dr. Eric R. Wagner, on their recently published study comparing two well- [...]
Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference
02/03/2026
BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that company management will participate [...]
Transactions in Connection with Share Buy-back Program
02/03/2026
Company Announcement COPENHAGEN, Denmark; March 2, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum [...]
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
02/03/2026
REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (Nasdaq: CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday [...]
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
02/03/2026
Conference Call and Webcast Scheduled for March 12, 2026 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage [...]
Ardena Appoints Paul Edwards as Chief People Officer
02/03/2026
Ghent, Belgium – March 2, 2026 – Ardena, a specialist pharmaceutical contract development and manufacturing organizatin (CDMO) and bioanalytical contract research organization (CRO) advancing precision medicines, today [...]
Tilray Brands Acquires BrewDog, a Leading Global Craft Brand, Creating a ~$500 Million Global Craft Beer and Beverage Platform
02/03/2026
Accretive Acquisition of Select Assets Includes Global Brand, UK Brewing Operations and 11 Strategic Brewpubs Expected to Generate ~$200 Million in Annual Net Revenue and ~$6 - $8 Million of Adjusted EBITDA in Fiscal [...]
RadNet Reports Fourth Quarter 2025 Results, Including Record Revenue and Adjusted EBITDA⁽¹⁾ and Releases 2026 Financial Guidance
02/03/2026
Total Company Revenue increased 14.8% to a quarterly record of $547.7 million in the fourth quarter of 2025 from $477.1 million in the fourth quarter of 2024; Revenue from the Digital Health reportable segment ( [...]
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
02/03/2026
Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaid Zymeworks to retain 70% of royalties [...]
RadNet Acquires Gleamer, Making RadNet’s DeepHealth the Largest Provider of Radiology Clinical AI Solutions Worldwide
02/03/2026
Based in Paris, France, Gleamer serves over 700 customer contracts worldwide with a broad portfolio of FDA-cleared and CE-marked solutions for musculoskeletal, breast, lung and neurologic applications. Gleamer’s [...]
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
02/03/2026
Supplemental Biologics License Application for Ziihera ® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) during 1Q 2026 in the U.S. with [...]

Pages